Tel Aviv University
Tel Aviv, Israel, 4641729
Location status: Recruiting
Location contact
Michal Kahn, PhD
CONTACT
Michal Kahn, PhD
PRINCIPAL_INVESTIGATOR
Shai Nimrodi, MA
CONTACT
=972-58-426-6060
NCT Number: NCT07048340
This randomized controlled trial will test the efficacy of CBT-I intervention for school-aged children (7-11 years old) with insomnia. The trial will focus on the role of sleep restriction therapy in treatment. Children will be randomized to one of three groups: (1) CBT-I; (2) CBT-I without SRT; or (3) a waitlist control group. Assessments will occur at baseline, mid-treatment, post-treatment, and a 3-month follow up. Some measures (e.g., child motivation) will also be assessed after each therapy session. Insomnia and sleep-wake patterns will be assessed objectively using actigraphy, and subjectively using sleep diaries, a clinical diagnostic interview, and questionnaires. Parent and child questionnaires will be administered to assess moderators and mediators of treatment outcomes.
Interested in participating?
Request Info7 year–11 year
All sexes
Interventional
Not applicable
Tel Aviv, Israel, 4641729
Location status: Recruiting
Michal Kahn, PhD
CONTACT
Michal Kahn, PhD
PRINCIPAL_INVESTIGATOR
Shai Nimrodi, MA
CONTACT
=972-58-426-6060
Insomnia stands out as the most prevalent sleep disorder in youth, inflicting a range of adverse consequences on both the child and the family. While cognitive-behavioral therapy for insomnia (CBT-I) is considered the first-line treatment, empirical investigations into its efficacy in school-aged children have been scarce. Moreover, the unique contributions and underlying mechanisms of individual treatment components of the CBT-I 'package' remain poorly understood. Sleep Restriction Therapy (SRT) is acknowledged as a core module of CBT-I in adults, presumably driving clinical change via increases in homeostatic sleep pressure that facilitate sleep onset and maintenance. Yet, the incremental benefits of SRT within the context of CBT-I have not been systematically examined. Similarly, the role of two key mechanisms in the CBT-I 'package'-pre-sleep hyperarousal and parental over-accommodation-as mediators of treatment outcome has not been investigated. As for treatment moderators, the frequently encountered lack of motivation among children to engage in therapy poses a notable barrier to effective insomnia treatment, a barrier that SRT may potentially alleviate by offering the appeal of a later bedtime. Given the unique characteristics of insomnia in school-aged children and the prominent role played by parents in etiology and treatment, understanding these processes is pivotal. The proposed dismantling trial is designed to address these issues by rigorously testing the efficacy of CBT-I, including and excluding the SRT module, meticulously examining underlying mechanisms, and determining which variation of the intervention may be more suitable for specific children.
A total of 120 children aged 7-11 with chronic insomnia disorder will be randomized to one of 3 study arms: (1) CBT-I; (2) CBT-I without SRT; or (3) a waitlist control group. Assessments will occur at baseline, mid- treatment, post-treatment, and 3-month follow-up. Insomnia and sleep-wake patterns will be assessed objectively via actigraphy, complemented by parent and child questionnaires, sleep diaries, and a clinical diagnostic interview. Additional factors will be measured, including the child's presleep hyperarousal, separation anxiety, behavioral and emotional problems, as well as parental accommodation, distress and anxiety, and cry tolerance. Some of these factors will be tested as possible mediators (pre-sleep hyperarousal, parental accommodation, child motivation to engage in treatment, and family adherence to treatment) and moderators (parent and child levels of emotional or behavioral problems at baseline) of treatment outcome. Parents' satisfaction with treatment will also be assessed at post-treatment. Participants allocated to the waitlist control group will all receive CBT-I after the 5-week waiting period.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CBT-I intervention will include four 45-60 minute sessions with a clinician. The sessions will include CBT-I components such as sleep psychoeducation, bedtime routines and sleep hygiene, graduated exposure, cognitive restructuring, and SRT in one of the intervention groups. The protocol is based on previous studies of CBT-I for school-aged children.
This intervention will include four 45-60 minute sessions with a clinician. The sessions will include CBT-I components such as sleep psychoeducation, bedtime routines and sleep hygiene, graduated exposure, and cognitive restructuring. Sleep Restriction Therapy will not be included in the intervention. The protocol is based on previous studies that delivered CBT-I to school-aged children.
Time frame: Baseline, post-treatment (5 weeks following baseline)
A structured interview with the child and parents will be conducted at both baseline and post-treatment by a blind clinical assessor. Based on ICSD-3 criteria, children will be diagnosed with chronic insomnia disorder if their sleep difficulties are evident on ≥3 nights per week, persisting for ≥3 months. The interview will additionally address sleep-related behaviors (e.g., reliance on parents for sleep onset), daytime consequences, and differential diagnosis. The clinical diagnosis of insomnia at baseline will serve to confirm that the child qualifies for inclusion in the trial. At post-treatment, the percentage of children no longer meeting the criteria for the disorder will be considered a primary outcome measure.
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Sleep efficiency will be measured using actigraphy and sleep diaries completed by parents. Sleep efficiency is computed as the percent of total sleep duration out of time in bed (including sleep onset latency and any wakefulness after sleep onset).
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Total nighttime sleep duration will be assessed using actigraphy
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Total nighttime sleep duration will be assessed using sleep diaries completed by parents.
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Number of nighttime awakenings will be assessed using actigraphy.
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
The number of nighttime awakenings will be assessed using daily sleep diaries filled by parents.
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Parents will report in daily sleep diaries whether co-sleeping (sharing a room or bed with the child) occured.
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Sleep behaviors and difficulties will be measured using the Children's Sleep Habit Questionnaire (CSHQ) - a 33-item parent-report measure of sleep behaviors and difficulties.
Time frame: Baseline, mid-treatment (3 weeks following baseline), and post-treatment (5 weeks following baseline).
Presleep Hyperarousal will be assessed using The Pre-Sleep Arousal Survey for Children (PSAS-C), administered to the child by clinicians.
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Both parents will complete The Family Accommodation Scale for Sleep- Parent Report (FASS-PR), and a total score will be computed, with higher scores indicating greater parental accommodation.
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Both parents will complete The Kalhish Questionnaire, measuring parental cognitions regarding child's anxiety. A total score will be computed, with higher scores indicating more parental cognitions endorsing accommodation.
Time frame: Baseline, mid-treatment (3 weeks following baseline), post-treatment (5 weeks following baseline), and follow-up (three months following baseline)
Child behavioral problems will be assessed using the Strengths and Difficulties Questionnaire (SDQ), parent version.
Time frame: Baseline and post-treatment (5 weeks following baseline)
Parent depression, anxiety, and stress symptoms will be assessed using the DASS-21.
Time frame: Baseline and post treatment (5 weeks following baseline)
Separation anxiety will be measured using 8 items from the separation anxiety subscale of the Screen for Childhood Anxiety Related Disorders questionnaire (SCARED).
Time frame: Baseline
Parents will undergo the Intervention Delay to Infant Crying Video (IDICV), which measures response time to a crying baby.
The IDICV includes a presentation of a 2-min video clip of a 6-month-old baby playing on a carpet who then starts crying (after 10s), with a gradual increase in crying intensity and visual distress signs. Directions prior to the video presentation include that the parents of the baby are trying to ignore some of his crying to allow him to calm down by himself, and participants are asked to decide when they feel that it is absolutely necessary to intervene.
Time frame: After each of the 4 therapy sessions, including session 1 (1 week after baseline), session 2 (2 weeks after basline), 3 (3 weeks after baseline), and 4 (5 weeks after baseline).
Parents will complete a questionnaire regarding their adherence to the treatment protocol after every session. Parent ratings will be averaged to create a parental adherence score, with higher scores indicating higher adherence to treatment.
Time frame: After each of the 4 therapy sessions, including session 1 (1 week after baseline), session 2 (2 weeks after basline), 3 (3 weeks after baseline), and 4 (5 weeks after baseline).
Therapists will evaluate the family's adherence to the treatment protocol after every session. Ratings will be averaged to create a family adherence score, with higher scores indicating higher adherence to treatment.
Time frame: After each of the 4 therapy sessions, including session 1 (1 week after baseline), session 2 (2 weeks after basline), 3 (3 weeks after baseline), and 4 (5 weeks after baseline).
Children will answer modified questions from the Child Motivation Scale, administered by the clinician. Ratings will be averaged to create a child motivation score, with higher scores indicating higher motivation for treatment.
Time frame: After each of the 4 therapy sessions, including session 1 (1 week after baseline), session 2 (2 weeks after basline), 3 (3 weeks after baseline), and 4 (5 weeks after baseline).
Therapists will also assess the motivation of the family (child and parents) on questionnaire items. Ratings will be averaged to create a family motivation score, with higher scores indicating higher motivation for treatment.
Time frame: After each of the 4 therapy sessions, including session 1 (1 week after baseline), session 2 (2 weeks after basline), 3 (3 weeks after baseline), and 4 (5 weeks after baseline).
Parents will answer questions regarding their satisfaction with the treatment and their relationship with the clinician. Ratings will be averaged to create a total satisfaction score, with higher scores indicating higher satisfaction from treatment.
Time frame: After each of the 4 therapy sessions, including session 1 (1 week after baseline), session 2 (2 weeks after basline), 3 (3 weeks after baseline), and 4 (5 weeks after baseline).
Children will answer questions regarding their satisfaction with the treatment after each session. Their ratings will be averaged to create a total satisfaction score, with higher scores indicating higher satisfaction from treatment.
Contact information is provided by the study sponsor or research team.
Michal Kahn, PhD
CONTACT
Shai Nimrodi, MA
CONTACT
Tel Aviv University
Other
The Role of Sleep Restriction Therapy in Cognitive-behavioral Therapy for Insomnia in School-aged Children: A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07735390
Dyssomnias, Insomnia
Tainan, Taiwan
View Trial DetailsNCT07299240
Basal Ganglia Diseases, Brain Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT07191119
Acute Lymphoblastic Leukemia (ALL), Dyssomnias
Memphis, Tennessee, United States
View Trial DetailsNCT07323121
Basal Ganglia Diseases, Brain Diseases
Nanjing, Jiangsu, China
View Trial Details